Become Affiliate

PepFlow

Download

The Skin Regenerator

GHK-Cu

The most-studied copper peptide in skincare: a naturally occurring tripeptide (GHK, Gly-His-Lys) whose best-known tissue form is the copper complex GHK-Cu, with extensive research supporting skin remodeling, collagen synthesis, wound-repair biology, and skin-aging applications.

SkinHairRecoveryInflammationAnti-aging
TierB
EvidenceModerate
SafetyModerate Data
FDA statusNot Approved
Topical 503AUnder Review
Last reviewed October 25, 2026 33 citations How to read these labels

What is GHK-Cu?

GHK is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, found in human plasma, saliva, and urine. It was originally isolated in 1973 by Loren Pickart as an activity in human albumin that made older human liver tissue synthesize proteins more like younger tissue.[9]

GHK binds strongly to copper(II), which is why the copper complex GHK-Cu is usually treated as its active tissue form. In skin and wound-repair research, review literature describes GHK-Cu as a remodeling signal: it appears to influence fibroblasts and other repair cells involved in collagen production, water-binding glycosaminoglycans, rebuilding the extracellular matrix, and repair-related gene activity.[9][3][4][5][11]

In casual skincare and peptide discussions, GHK and GHK-Cu are often used as if they mean the same thing. More precisely, GHK is the bare Gly-His-Lys tripeptide, while GHK-Cu is the copper-chelated complex. Product and ingredient labels may also use names such as copper peptide, copper tripeptide-1, Cu-GHK, or Gly-His-Lys-Cu.[9]

Interest in GHK-Cu also comes from its natural decline with age. A skin-regeneration review reports plasma GHK around 200 ng/mL at age 20 and about 80 ng/mL by age 60. That decline helps explain the interest in replenishment-focused skin and repair research, but it does not prove that every GHK-Cu route or product reverses aging.[9][27] For more context, read the GHK-Cu mixing and handling explainer.

What GHK-Cu is investigated for

GHK-Cu evidence is grouped by practical use case and topical, injectable, intranasal, transdermal, and intra-articular route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Skin appearance and texture

Topical

65%Moderate

It is reasonable to describe topical GHK-Cu as one of the better-supported cosmetic peptides for skin appearance and matrix-support research. Product-level guarantees should still be avoided because delivery, concentration, and formulation vary.[5][16][6][3][8]

Human evidence

Human evidence includes cosmetic and dermatology reviews plus one small randomized post-CO2-laser study with 13 completed patients. In that study, objective redness, wrinkle, and overall skin-quality measures were not better than control, while patient-reported overall skin-quality improvement was higher with GHK-Cu skincare.[5][6]

Animal / mechanistic evidence

Fibroblast, glycosaminoglycan, tissue-remodeling, delivery, and anti-wrinkle literature support a coherent explanation for how GHK-Cu could affect the skin matrix, especially when the formula can deliver the peptide to living skin layers.[3][4][5][16][15]

Acute wound repair

Topical

49%Preliminary

Topical wound-healing use is a legitimate research area and should be described as under investigation until the Phase 2 trial or comparable human wound studies report results.[19][10]

Human evidence

ClinicalTrials.gov lists a recruiting Phase 2, randomized, double-blind, vehicle-controlled split-wound study in an estimated 60 healthy adults. The study uses 0.1% w/w topical GHK-Cu gel once daily for 14 days, and no results are posted.[19]

Animal / mechanistic evidence

Repair-biology reviews and a mouse scald-wound study support wound-healing research interest, including faster healing with GHK-Cu liposomes than comparator conditions. Animal wound findings still do not establish human clinical effectiveness.[5][10]

Hair and scalp support

Topical

35%Preliminary

Hair and scalp claims can be presented as emerging mechanism-based interest, not as a supported hair-loss treatment.[5][9]

Human evidence

No GHK-Cu-specific controlled human hair-growth outcome source is included.

Animal / mechanistic evidence

Reviews discuss hair follicles, follicle size, and repair biology, but that is not enough to support GHK-Cu as a validated clinical hair-growth treatment.[5][9]

Cellular anti-aging and systemic repair claims

Injectable

10%Insufficient

Available sources do not establish injectable GHK-Cu for systemic repair or anti-aging outcomes. Injectable use should be treated separately from topical cosmetic use and topical wound research.[27]

Human evidence

FDA describes limited human safety data for compounded injectable drugs containing GHK-Cu.[27]

Animal / mechanistic evidence

Preclinical and review literature supports broad repair biology, but it does not establish systemic injectable safety, dosing, or effectiveness in humans.[5][11][27]

Evidence snapshot

45%

Human evidence

Emerging

Human data are still limited: reviews, one small post-CO2-laser study, and a recruiting topical wound trial. This supports topical research interest, not a settled clinical effect size.[5][6][19]

82%

Animal / preclinical

Strong

Preclinical support is stronger than human evidence. Cell, animal, and formulation studies support collagen, matrix repair, skin delivery, and wound-healing biology.[3][4][5][10][8]

88%

Mechanism support

Strong

The mechanism story is one of GHK-Cu's stronger areas. Reviews link it with collagen, water-binding matrix molecules, tissue remodeling, and repair-related gene activity.[3][4][5][11]

Forms & administration

GHK-Cu appears in topical cosmetics and investigational skin gels, with absorption depending on formulation. Nasal, joint-delivery and assisted skin-delivery approaches remain experimental, with laboratory or animal evidence. Compounded injectable preparations have a less established human safety and efficacy base than topical products.[24][19][15][8][27][20][21]

TopicalInjectableNasal sprayTransdermalIntra-articular

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Topical products usually contain 1-3% GHK-Cu. Injectable protocols commonly use 1-2 mg per dose.[16][27]

Frequency

Topical products are usually applied 1-2 times daily. Injectable protocols commonly use 1-2 doses daily.[6][27]

Timing Considerations

Use a consistent morning or evening schedule.[6][27]

Cycle Length

Assess topical use after 8-12 weeks. Injectable cycles commonly run 4-12 weeks.[6][27]

What to expect

First 1-2 weeks

Surface-level comfort: smoother feel, better hydration, and calmer-looking skin as the routine settles in.[16][9]

Weeks 4-8

Visible gradual texture and tone improvements, softer-looking fine lines, and a more even post-procedure appearance.[6][16]

Weeks 8-12

Clearest before-and-after comparison of texture, barrier feel, and overall skin smoothness, with continued use functioning more like maintenance.[5][9][16]

After stopping

Fading surface hydration and barrier-feel improvements as the topical routine is removed, with deeper cosmetic effects softening gradually through normal skin turnover and changes in the rest of the skincare routine.[16][6]

Safety profile

Topical cosmetic GHK-Cu is mainly a local-tolerance question: irritation, stinging, redness, itching, or sensitivity. Injectable or systemic GHK-Cu is a different safety category because FDA flags limited human safety data and immunogenicity concerns for compounded injectable products; copper-handling disorders add another systemic caution.[24][27][19][29]

Common side effects

  • Irritation / redness / stinging[6][8]
  • Injectable safety uncertainty[27]

Cautions

  • Copper-handling disorders (systemic)[29]
  • Injectable purity and immunogenicity[27]

What we don't know

The unresolved safety questions are long-term injectable exposure, controlled human dose-ranging, route-specific interactions, and product purity. For topical products, uncertainty is mostly formulation-level: vehicle, pH, delivery method, copper loading, and actual peptide content can change tolerability and performance.[15][8][27]

Who GHK-Cu is not for

Route-specific avoid and medical-review notes:

  • Copper-handling disorders

    Systemic or injectable GHK-Cu is not a fit for people with Wilson disease or other copper-handling disorders unless a qualified clinician specifically reviews it. Wilson disease prevents the body from removing extra copper, so copper-containing systemic exposure needs separate medical review.[29][27]

  • Pregnancy or breastfeeding (systemic use)

    Pregnancy or breastfeeding is a medical-review situation for systemic or injectable GHK-Cu because human safety data for that route are not established.[27]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Copper-control or copper-removal treatment

    Anyone being treated to lower or control copper burden should treat systemic GHK-Cu as a clinician-review interaction. This is not a proven drug-drug interaction; it is a theoretical copper-burden concern because GHK-Cu is a copper-containing peptide.[29]

Pairing notes

Works well with

Hyaluronic acidTopical

GHK-Cu and low-molecular-weight hyaluronic acid complement one another in topical formulations by supporting collagen IV production and skin-matrix structure.[13]

Commonly included in these stacks

Not recommended with

Additional copper peptides or copper complexesInjectable

Compounded injectable GHK-Cu has limited human safety data and potential immunogenicity concerns from aggregation and peptide-related impurities. Additional injectable copper-peptide or copper-complex products require separate formulation review because compatibility and combined exposure are not established.[27]

How it works

GHK-Cu is mainly discussed for slower skin-remodeling and repair biology, not for an instant cosmetic feel. It is a small copper-binding peptide complex studied for how it affects repair signaling around skin cells. The practical story starts with fibroblasts, the cells that help build and remodel collagen and other matrix components.[9][3][4][5]

Much of the evidence points toward extracellular-matrix remodeling. In plain terms, GHK-Cu appears to influence the scaffold around cells: collagen for structure, glycosaminoglycans for water-binding support, and remodeling enzymes that break down and rebuild matrix. That is why claims around texture, firmness, procedure recovery, and wound biology take weeks and depend heavily on delivery.[3][4][5][10][8]

Delivery is the route-specific bottleneck. Topical products must move through the stratum corneum, and studies of liposomes, microneedles, and other systems exist because passive penetration is limited. Injectable or systemic use bypasses that skin barrier, but it also enters a less-supported safety and dosing category.[15][8][14][27]

Gene-expression and anti-aging reviews widen the biological story, but they should not be read as direct clinical proof. The stronger claim is local skin and repair biology; broader systemic anti-aging, injury-recovery, or hair-growth outcomes remain unproven in humans.[11][12][27]

Research gaps & open questions

What the current literature has not yet settled about GHK-Cu:

01

Controlled trials should compare topical concentrations, bases, and delivery systems to show which formulas actually improve wrinkles, scars, skin quality, or wound healing in people.[16][6][19]

02

Injectable GHK-Cu lacks basic human evidence: which dose reaches tissues, how long it remains in the body, whether it works, and whether repeated exposure or impurities cause harm.[27]

03

It is not known whether a serum, liposomal product, microneedle system, wound gel, and injection deliver comparable amounts or effects; products should not be treated as interchangeable.[15][8]

04

Controlled studies need to show whether GHK-Cu improves hair density or growth in people; current interest is based mainly on mechanism.[5][9]

Common questions

Is GHK-Cu the same thing as GHK?

They are related, but not identical. GHK is the bare glycyl-L-histidyl-L-lysine tripeptide; GHK-Cu is the copper-bound complex. Skincare sources often use the names loosely, but the copper complex is the form most often discussed for skin remodeling and repair.[9]

What is GHK-Cu best known for?

GHK-Cu is best known for topical skin remodeling, collagen and matrix biology, procedure-recovery research, and wound-repair biology. The strongest support is mechanism, review, and preclinical evidence, with more limited topical human outcome data.[9][3][6]

Does topical GHK-Cu evidence support injectable use?

No. Topical GHK-Cu evidence does not carry over to injections. FDA lists injectable GHK-Cu separately in safety-risk materials, citing potential immunogenicity and limited human safety data.[27]

Is GHK-Cu FDA-approved?

Not approved for human use as a drug. Topical cosmetics are a separate regulatory category, and current 503A compounding materials distinguish non-injectable GHK-Cu from injectable GHK-Cu.[22][23][24][25][27]

Is GHK-Cu supported for hair growth?

Not yet as a validated hair-loss treatment. Reviews discuss follicle-related biology, but the reviewed set does not include a controlled GHK-Cu human hair-growth outcome study.[5][9]

Myths & misconceptions

Myth

Because GHK-Cu affects gene-expression pathways, it is proven as a systemic anti-aging therapy.

Reality

Gene-expression data show pathways worth studying. They do not prove that injectable or systemic GHK-Cu slows aging or improves whole-body outcomes in humans.[11][27]

Myth

Topical cosmetic use and injectable use have the same evidence and risk profile.

Reality

Topical cosmetic use stays mostly in local-skin and formulation questions. Injectable use creates different exposure, product-quality, immunogenicity, dosing, and regulatory questions.[24][27]

Myth

All copper peptide products are basically the same.

Reality

Copper-peptide products can differ in peptide form, copper loading, pH, vehicle, encapsulation, and delivery method. Evidence for one formula should not be copied to all copper-peptide products.[15][8]

History & discovery

GHK-Cu's history begins with GHK, the naturally occurring Gly-His-Lys tripeptide isolated by Loren Pickart in the 1970s during work on why young plasma appeared to restore more youthful protein-synthesis patterns in older liver tissue. The copper complex later became the form most associated with collagen, glycosaminoglycans, extracellular-matrix remodeling, cosmetic skin use, and repair-biology research.[1][2][5][9]

GHK entered the literature as a plasma-derived signal that appeared to change protein synthesis and cell behavior, not as a conventional approved drug. That origin matters because later GHK-Cu interest grew from endogenous repair signaling and cell biology.[1][2]

The copper-bound form became central as fibroblast studies reported effects on collagen and sulfated glycosaminoglycan synthesis. Those findings moved GHK-Cu into skin-matrix, wound-repair, and tissue-remodeling research.[2][3][4]

The modern story is route-specific. Topical cosmetic and investigational wound uses sit in a different evidence and regulatory bucket from injectable or systemic use. Current U.S. compounding materials keep that distinction visible by treating non-injectable GHK-Cu separately from injectable GHK-Cu safety-risk concerns.[9][25][27]

Published research33 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay consistent with your skin-care goals.

Use PepFlow to record your GHK-Cu protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00